In-vitro Study Shows Ozenoxacin Effective Against Drug-Resistant Skin Infection Bacteria
A bioRxiv preprint reports that ozenoxacin, a novel non-fluorinated topical quinolone, demonstrated potent in vitro activity against 109 Staphylococcus aureus and 24 Streptococcus pyogenes isolates from skin and soft-tissue infections, outperforming 8 of 9 comparator antibiotics including vancomycin and linezolid. The study used broth microdilution testing on clinical isolates including methicillin-resistant strains (MRSA), finding ozenoxacin MIC90 of 0.5 µg/ml compared to 2 µg/ml and 4 µg/ml for vancomycin and linezolid respectively. The findings are relevant given rising resistance to commonly used topical antibiotics such as mupirocin and fusidic acid.
Researchers tested ozenoxacin, a first-in-class non-fluorinated quinolone approved for topical use, against clinical isolates of Staphylococcus aureus and Streptococcus pyogenes collected from skin and soft-tissue infections, wounds, abscesses, and blood. Using broth microdilution methods per CLSI guidelines, the study found ozenoxacin achieved MIC50/90 values of 0.125/0.5 µg/ml against all 109 S. aureus isolates and 0.015/0.03 µg/ml against 24 S. pyogenes isolates. Notably, the drug maintained activity against methicillin-resistant S. aureus (MRSA), a strain of particular clinical concern. By contrast, fusidic acid and mupirocin — two widely used topical antibiotics — showed higher minimum inhibitory concentrations in a subset of S. aureus isolates, reflecting existing resistance trends. Ozenoxacin's MIC90 of 0.5 µg/ml was lower than 8 of the 9 comparator agents tested, including systemic agents vancomycin and linezolid. The authors conclude that these in vitro findings support ozenoxacin as a promising topical therapeutic option for managing skin and soft-tissue infections caused by resistant organisms.
What's missing
This is a preprint and has not yet undergone peer review. The study is limited to in vitro testing; no clinical or pharmacokinetic data are presented to confirm that in vitro potency translates to in vivo efficacy or safety. The sample size is relatively small (109 S. aureus and 24 S. pyogenes isolates), and the geographic and demographic sources of the clinical isolates are not described, limiting generalizability. No resistance mechanism analysis or pharmacodynamic modeling is included.
What different sources said
- bioRxivCenter
In-vitro evaluation of Ozenoxacin and other Antibiotics against Staphylococcus aureus and Streptococcus pyogenes isolated from Skin and Soft Tissue Infections
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.